NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $101.35 -0.04 (-0.04 %) (As of 02/21/2020 03:07 AM ET) Add Compare Today's Range$99.68Now: $101.35▼$103.2150-Day Range$86.54MA: $93.63▼$104.7552-Week Range$84.45Now: $101.35▼$130.50Volume273,391 shsAverage Volume323,502 shsMarket Capitalization$1.78 billionP/E Ratio3.45Dividend YieldN/ABeta1.32 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND Previous Symbol CUSIP53220K50 CIK886163 Webhttp://www.ligand.com/ Phone858-550-7500Debt Debt-to-Equity Ratio0.85 Current Ratio66.09 Quick Ratio65.66Price-To-Earnings Trailing P/E Ratio3.45 Forward P/E Ratio44.65 P/E Growth2.88 Sales & Book Value Annual Sales$120.28 million Price / Sales14.80 Cash Flow$3.44 per share Price / Cash Flow29.43 Book Value$43.68 per share Price / Book2.32Profitability EPS (Most Recent Fiscal Year)$2.11 Net Income$629.30 million Net Margins523.19% Return on Equity4.34% Return on Assets2.41%Miscellaneous Employees116 Outstanding Shares17,563,000Market Cap$1.78 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive LGND News and Ratings via Email Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LGND Rates by TradingView Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Inc. (NASDAQ:LGND) posted its earnings results on Thursday, February, 6th. The biotechnology company reported $0.71 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.64 by $0.07. The biotechnology company had revenue of $27 million for the quarter, compared to analyst estimates of $25.30 million. Ligand Pharmaceuticals had a net margin of 523.19% and a return on equity of 4.34%. The business's revenue for the quarter was down 54.7% compared to the same quarter last year. During the same period last year, the business posted $1.70 earnings per share. View Ligand Pharmaceuticals' Earnings History. When is Ligand Pharmaceuticals' next earnings date? Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Ligand Pharmaceuticals. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of Approx $3.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.49. The company issued revenue guidance of Approx $121 million, compared to the consensus revenue estimate of $126.51 million. What price target have analysts set for LGND? 5 equities research analysts have issued twelve-month price targets for Ligand Pharmaceuticals' stock. Their forecasts range from $132.00 to $237.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $164.80 in the next twelve months. This suggests a possible upside of 62.6% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals. What is the consensus analysts' recommendation for Ligand Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals. What are Wall Street analysts saying about Ligand Pharmaceuticals stock? Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock: 1. According to Zacks Investment Research, "Ligand reported encouraging second-quarter results with earnings and sales beating estimates. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Ligand is acquiring other technology platforms like OmniAb platform from OMT acquisition to reduce dependence on Captisol formulation. OmniAb is likely to drive future revenues. However, Shares of Ligand have underperformed the industry so far this year. Moreover, Ligand derives a substantial portion of its revenues from royalties associated with the sales of Kyprolis. Any setback to Kyprolis will have an unfavorable impact on the top line. Moreover, increase in inactive licensing deals related to Ligand’s technology platform raises concerns." (8/8/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $214 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (5/3/2019) Has Ligand Pharmaceuticals been receiving favorable news coverage? Media headlines about LGND stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Ligand Pharmaceuticals. Who are some of Ligand Pharmaceuticals' key competitors? Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Illumina (ILMN), Netflix (NFLX), Gilead Sciences (GILD), AbbVie (ABBV), Intel (INTC) and salesforce.com (CRM). Who are Ligand Pharmaceuticals' key executives? Ligand Pharmaceuticals' management team includes the folowing people: Mr. John L. Higgins, CEO & Exec. Director (Age 49)Mr. Matthew W. Foehr, Pres & COO (Age 46)Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. Todd Pettingill, Director of Corp. Devel. Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (10.35%), William Blair Investment Management LLC (8.07%), Renaissance Technologies LLC (5.81%), Conestoga Capital Advisors LLC (3.53%), Thrivent Financial for Lutherans (3.01%) and Rice Hall James & Associates LLC (1.72%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba, Sunil Patel and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals. Which major investors are selling Ligand Pharmaceuticals stock? LGND stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Renaissance Technologies LLC, AJO LP, Victory Capital Management Inc., Victory Capital Management Inc., AQR Capital Management LLC, Sei Investments Co. and CIBC Private Wealth Group LLC. View Insider Buying and Selling for Ligand Pharmaceuticals. Which major investors are buying Ligand Pharmaceuticals stock? LGND stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Thrivent Financial for Lutherans, William Blair Investment Management LLC, California Public Employees Retirement System, KBC Group NV, Eaton Vance Management, Tygh Capital Management Inc. and Credit Suisse AG. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins and Sunil Patel. View Insider Buying and Selling for Ligand Pharmaceuticals. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $101.35. How big of a company is Ligand Pharmaceuticals? Ligand Pharmaceuticals has a market capitalization of $1.78 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.View Additional Information About Ligand Pharmaceuticals. What is Ligand Pharmaceuticals' official website? The official website for Ligand Pharmaceuticals is http://www.ligand.com/. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected] MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 482 (Vote Outperform)Underperform Votes: 351 (Vote Underperform)Total Votes: 833MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: How can investors find ex-dividend dates?
